QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
by Zacks Equity Research
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
QIAGEN Partners Inovio to Develop Companion Diagnostics
by Zacks Equity Research
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Qiagen (QGEN) Tops Q1 Earnings Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 3.85% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for QIAGEN (QGEN)
by Zacks Equity Research
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
by Zacks Equity Research
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Why Is Qiagen (QGEN) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Qiagen (QGEN) Q4 Earnings Meet Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
by Zacks Equity Research
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE